Telomerase Activation in Hematological Malignancies

Ropio, Joana; Merlio, Jean-Philippe; Soares, Paula; Chevret, Edith

doi:10.3390/genes7090061

Cited by 25 publications

(18 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence in this study, we used hTERT detection to assess the telomerase activity by TRAP assay in both B-CLL patients and control individuals, and it showed that the hTERT expression detected in 34 (79.1%) patients and it was significantly higher than the control group which did not show any hTERT expression and this result is higher than Tchirkov A (Tchirkov, 2004) result which showed 59% of B-CLL patients expressed hTERT and this disparity may be related to difference between the methods that used for hTERT detection. Also, the hTERT expression in our research is correlated with other researchers that identified hTERT expression in patients malignancy in compared to normal individuals (Ropio, 2016;Bruedigam, 2016).…”

Section: Discussionsupporting

confidence: 87%

The Expression of Human Telomerase Reverse Transcriptase Gene and Its Activity in Patients with B-Cell Chronic Lymphocytic Leukemia and Its Impact on Clinical Staging

AlJabban

Alalsaidissa

2018

GJHS

View full text Add to dashboard Cite

Background: The B-Cell chronic lymphocytic leukemia is a commonest leukemia in elderly individuals characterized by progressive accumulation of mature lymphocyte in bone marrow and peripheral blood that tend to be immortal. The identification of human telomerase reverse transcriptase (hTERT) has been correlated with disease aggressiveness in malignancies. The previous researchers showed that the hTERT expression could serve as a molecular prognostic marker for B-CLL patients. However, due to the disease differences in prevalence and aggressiveness between the western and eastern countries, there is still a need to see the correlation of hTERT in B-CLL patients of the eastern world. Aim:To test the quantitative assessment of hTERT gene expression in B-CLL patients and its prognostic value in correlation with clinical staging of disease in Iraqi patients. Patients and Methods:we used the TRAP assay to assess the hTERT gene expression in mononuclear blood cells from 43 B-CLL patients. Results:The hTERT gene expression was detected in 79.1% of B-CLL patients and no positive expression in control group (P=0.001). The hTERT gene expression tends to be significantly higher in advanced B-CLL stage (P=0.0001). Also, the expression was higher among elderly patients, patients with lower hematological parameters, patients with splenomegaly or hepatomegaly, patients with a history of hypertension or diabetes mellitus, and patients with high immunophenotype score. Conclusion:Our research suggests that the hTERT expression could serve as a prognostic marker for Iraqi patients with B-CLL as well as western countries.

show abstract

Section: Discussionsupporting

confidence: 87%

The Expression of Human Telomerase Reverse Transcriptase Gene and Its Activity in Patients with B-Cell Chronic Lymphocytic Leukemia and Its Impact on Clinical Staging

AlJabban

Alalsaidissa

2018

GJHS

View full text Add to dashboard Cite

show abstract

“…Telomerase activity and hTERT appears as a key event in the development and progression of the many diseases, whereas in acute myeloid leukemia (AML), in chronic myeloid leukemia (CML) and in B-cell diseases, it was demonstrated that telomerase activity is not required for the initiation of disease, but it is required for its maintenance (Ropio, Merlio, Soares, & Chevret, 2016).…”

Section: Introductionmentioning

confidence: 99%

The Expression of Human Telomerase Reverse Transcriptase in Adult Acute Myeloid Leukemia and Its Correlation With Various Clinico-Pathological Parameters

AlJobori¹,

Jaafar²

2019

GJHS

View full text Add to dashboard Cite

BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors (blasts) in the bone marrow and peripheral blood, AML accounts for 80% of acute leukemia in adults, its incidence increase with age. AML can be a fatal disease so research to predict prognosis is important. Telomerase (TA) is an enzyme that stabilizes the telomere length and makes the cell immortal. It is present in some of the normal cells, fetal cells, adult germ cells, and presents in 85% of tumors in humans, it has been shown that TA can be used as a prognostic marker in some solid and hematological neoplasms. Telomere length is a factor that predicts telomere function. AIM: We test the quantitative amount of human telomerase reverse transcriptase (hTERT) gene expression in AML (diagnosed according to FAB) adult and its correlation with various clinic-pathological parameters. PATIENTS & METHODS: We used the TRAP assay to assess the hTERT gene expression in mononuclear blood cells from 40 newly diagnosed AML patients, 25 AML patients after completing their course of treatment, and 15 control health subjects. RESULTS: The mean value of hTERT in AML and control groups were [1.59 ± 1.27 anm and 0.035 ± 0.046 anm respectively], and this difference was significantly higher in patients than in control group (p = 0.0001). The telomerase activity was positive in 27 (67.5%) AML patients, while 13 (32.5%) AML patients were negative for telomerase activity. Twenty-five patients after induction chemotherapy were followed up by bone marrow and peripheral blood examination to determine the patient’s response to therapy. Complete hematological remission was achieved in 12 (48.0%) patients and incomplete hematological remission in 13 (52.0%) patients (14%). The hTERT level was significantly higher in patients before induction chemotherapy than after completion of the induction course (p = 0.0001). The hTERT level at diagnosis in patients who did not achieve complete hematological remission was significantly higher than that in patients who achieved complete hematological remission (p = = 0.026). The hTERT level after induction therapy was significantly higher in patients who did not achieve complete hematological remission than in patients who achieved complete hematological remission (p = 0.003). CONCLUSION: Our research suggests that the hTERT expression could serve as a prognostic marker for AML patients. 

show abstract

“…Every cell division is accompanied by shortening of telomere sequences resulting in an "end replication problem" which triggers the activation of DNA damage pathways leading to senescence and subsequent cell death. Telomere erosion and replicative senescence limit cellular proliferation, which is considered an essential tumor-suppressive mechanism [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…Telomerase expression actively maintains telomere length and hence is crucial for cellular proliferation and survival. Overexpression of telomerase plays an important role in the development of cancer, including hematological malignancies [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Telomerase reverse transcriptase gene amplification in hematological malignancies

Abdelrahman

Eid

Hassan

et al. 2019

Egypt J Med Hum Genet

View full text Add to dashboard Cite

Background: Telomere is a complex DNA-protein structure located at the end of all eukaryotic chromosomes. The major role of human telomerase is to catalyze the addition of telomeric repeat sequences TTAGGG onto chromosome ends for stabilization of telomere length in attaining cellular immortality and may therefore be a critical step in carcinogenesis. Expression of significant levels of telomerase can dramatically increase proliferative life span and promote cellular immortality, thereby contributing to the malignant phenotype. The purpose of this study is to investigate telomerase reverse transcriptase (TERT) gene amplification in hematological neoplasms, e.g., multiple myeloma (MM), B-non-Hodgkin lymphoma (B-NHL), and acute myeloid leukemia (AML), using FISH technique and to evaluate its potential use as a prognostic marker. Results: TERT amplification was detected in all groups of the participant patients (15 MM, 15 B-NHL, and 15 AML patients), with higher incidence in AML patients (53.3%). A significant association between the pattern of presentation and telomerase amplification was detected in 88.9% of the relapsed patients who demonstrated amplification of TERT. TERT amplification shows a significant association with p53 deletion and a highly significant association with poor prognosis. Conclusions: TERT gene amplification is significantly associated with hematological malignancies and may play a critical role in carcinogenesis; thus, elucidation of their regulatory mechanism is highly demanding. Higher amplification was found in relapsed cases than de novo cases which highlight its potential implication in clinical analysis and disease monitoring. Moreover, our results suggest the future use of TERT gene as a potential prognostic marker that may aid in treatment decision and chemotherapy.

show abstract

Telomerase Activation in Hematological Malignancies

Cited by 25 publications

References 111 publications

The Expression of Human Telomerase Reverse Transcriptase Gene and Its Activity in Patients with B-Cell Chronic Lymphocytic Leukemia and Its Impact on Clinical Staging

The Expression of Human Telomerase Reverse Transcriptase Gene and Its Activity in Patients with B-Cell Chronic Lymphocytic Leukemia and Its Impact on Clinical Staging

The Expression of Human Telomerase Reverse Transcriptase in Adult Acute Myeloid Leukemia and Its Correlation With Various Clinico-Pathological Parameters

Telomerase reverse transcriptase gene amplification in hematological malignancies

Contact Info

Product

Resources

About